Velmanase alfa (Lamzede)

Status:

Red

Decision Date:

November 2021

Comments

RED: Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.

See NICE Guidance HST29 for further information.

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again